SCHEMBL9038701

SCHEMBL9038701

CCCCCCCCCCCCCCCCn1cnc2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.68
SMN1; SMN2 Q16637 7/20 0.63
LMNA P02545 4/20 0.63
ALOX15 P16050 1/20 0.63
TSHR P16473 1/20 0.63
HTT P42858 4/20 0.61
MAPT P10636 3/20 0.61
STAT3 P40763 1/20 0.61
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
NPC1 O15118 1/20 0.55
NFKB1 P19838 1/20 0.55
RAB9A P51151 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
SLC9A1 P19634 2/20 0.54
EGLN3 Q9H6Z9 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
DRD2 P14416 1/20 0.52
DRD4 P21917 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9853294 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL3868979 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL595111 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL9038339 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL6321085 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL11408718 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL9853336 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL4888041 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL16097150 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL9853222 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0262343-B1 N-alkylated quaternary nitrogen-containing heterocycles, process for their preparation and their use in pharmaceutical compositions PUETTER MEDICE CHEM PHARM (DE) 1996-01-03 EP claimed
WO-2024181373-A1 METHOD FOR SELECTIVELY MODIFYING SUBSTRATE SURFACE, METHOD FOR PRODUCING SURFACE-TREATED SUBSTRATE, AND COMPOSITION JSR株式会社 2024-09-06 WO disclosed
US-10752648-B2 Magnetic ionic liquids, methods of making and uses thereof as solvents in the extraction and preservation of nucleic acids THE UNIVERSITY OF TOLEDO (US) 2020-08-25 US disclosed
US-20190194643-A1 Magnetic Ionic Liquids, Methods of Making and Uses Thereof as Solvents in the Extraction and Preservation of Nucleic Acids THE UNIVERSITY OF TOLEDO (US) 2019-06-27 US disclosed
US-10280416-B1 Magnetic ionic liquids, methods of making and uses thereof as solvents in the extraction and preservation of nucleic acids THE UNIVERSITY OF TOLEDO (US) 2019-05-07 US disclosed
CN-108360085-A Anti-oxidant fiber of a kind of polyphenylene sulfide based on laminar nano particle and preparation method thereof 安徽工程大学 2018-08-03 CN disclosed
CN-106832931-A A kind of exfoliated polyphenylene sulfide/Nano composite material of montmorillonite and preparation method thereof 江南大学 2017-06-13 CN disclosed
EP-0262343-B1 N-alkylated quaternary nitrogen-containing heterocycles, process for their preparation and their use in pharmaceutical compositions PUETTER MEDICE CHEM PHARM (DE) 1996-01-03 EP disclosed
US-5133973-A Quaternary Ammonium Cationic Surfactants, Antimetabolites MEDICE CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) 1992-07-28 US disclosed
US-5118808-A Pharmaceutical preparations MEDICE CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) 1992-06-02 US disclosed
US-5051435-A Micelles of triazolium compounds as cationic surfactants MEDICE CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) 1991-09-24 US disclosed
US-5045530-A Conprising a micelle or a vesicle of a cationic teniside based on a hydrophobic alkyl-substituted pyridinium compound and a hydrophobic drug; drug delivery; skin disorders MEDICI CHEM.-PHARM. FABRIK PUTTER GMBH (DE) 1991-09-03 US disclosed
US-4999435-A Cationic Surfactants, Drugs, Immunoassay MEDICE CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) 1991-03-12 US disclosed
US-4965357-A CATIONIC TENSIDES, ANTIMETABOLITES MEDICE CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) 1990-10-23 US disclosed
US-4894454-A BACTERICIDES MEDICE CHEM.-PHARM. FABRIK, PUTTER GMBH & CO., KG (DE) 1990-01-16 US disclosed
US-4882435-A CATIONIC TENSIDES; THIADIAZOLIUM SALTS MEDICE CHEM.-PHARM. FABRIK (DE) 1989-11-21 US disclosed
US-4877883-A CATIONIC SURFACTANTS MEDICE CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) 1989-10-31 US disclosed
US-4874850-A CATIONIC TENSIDES IN MICELLES WITH HYDROPHOBIC PEPTIDES; DRUG DELIVERY MEDICE CHEM.-PHARM. FABRIK PUTTER GMBH & CO. (DE) 1989-10-17 US disclosed
US-4870174-A CATIONIC SURFACTANTS, SMALL CRITICAL MICELLE CONCENTRATIONS MEDICE CHEM.-PHARM. FABRIK (DE) 1989-09-26 US disclosed
US-4460709-A Process for producing oxygen-containing organic compounds AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) 1984-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10752648-B2 Magnetic ionic liquids, methods of making and uses thereof as solvents in the extraction and preservation of nucleic acids POLRMT, HNRNPH3, HNRNPL TDP1 382/4885SMN1; SMN2 113/4885LMNA 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.